# Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer

Source: https://onco.cc/trials/nct06233877/  
OnCo record `nct06233877` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of mitomycin C in pancreatic cancer, run by Hirschfeld Oncology, not yet recruiting.

## Summary

Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer is a phase 2, interventional study registered as NCT06233877 by Hirschfeld Oncology, with a registry enrolment figure of 60 participants, started 2024-03-15 and due to reach its primary completion in 2027-01-31. Interventions recorded: G-GLIP plus Mitomycin C. Conditions listed: Pancreatic Cancer. Primary outcome: Overall Survival; Response Rate. Pancreatic eligibility wording from the registry: "* Histologically confirmed metastatic (Stage IV) pancreatic adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: GFLIPM
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06233877
- Phase: 2
- Setting: An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability, and Efficacy of Low Dose G-FLIP in Combination With Mitomycin C in Patients With Stage IV Pancreatic Cancer Who Have Failed First-Line Treatment
- Sponsor: Hirschfeld Oncology
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06233877: https://clinicaltrials.gov/study/NCT06233877

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Mitomycin C](https://onco.cc/drugs/mitomycin/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06233877.json